Concurrent use of SGLT-2 inhibitors and RAS blockers

Jürgen Floege

Jürgen Floege, MD, is a professor of medicine, director of the Division of Nephrology and Clinical Immunology at the University Hospital RWTH Aachen, Germany, and Distinguished Fellow of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA).

In the context of the latest data on the efficacy of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in chronic kidney disease (CKD), do you think that an angiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor blocker (ARB) must always be used first, or can an SGLT-2 inhibitor be the upfront treatment?

A very good question. Should one start sequentially or should we start with an SGLT-2 inhibitor together with a renin–angiotensin system (RAS) blocker?

And I must say that I’ve recently changed my practice. I no longer wait for the RAS blocker to work and then start the SGLT-2 inhibitor. I start them in parallel and I believe, given that they have a synergistic action, there’s no reason not to do this.

See also

We would love to hear from you

Comments, mistakes, suggestions?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.